Global Cord Blood and Tissue Banking Industry Report 2022

1.1 Statement of the Report
1.2 Executive Summary
1.3 Introduction
1.3.1  Cord Blood: An Alternative Source for Hematopoietic Stem Cell Transplantation (HSCT)
1.3.2  Utilization of Cord Blood Cells within Clinical Trials
1.3.3  Challenges of Cord Blood Banking
1.3.4  Emerging Technologies that Support the Financial Sustainability of Cord Blood Banks
1.3.4.1  Strategic Opportunities that Improve the Financial Stability of Cord Blood Banks
1.3.4.2  Scope for Companion Products for Cord Blood Banks
1.3.5  Evolving Landscape for Cord Blood and Tissue Banking, by Geography
1.3.6  Product and Service Extensions Offered by Cord Blood Banks
1.4   Current Status of the Cord Blood and Tissue Banking Industry
1.4.1 Diversification of Cord Blood and Tissue (CBT) Products & Services
1.4.2  Pairing with Genetic Testing Services
1.4.3  Pairing with Fertility and Assisted Reproduction Services
1.4.4  Cord Blood and Tissue Banking Industry Consolidation
1.4.5  Cord Blood Banks as Integrated Therapeutic Companies2. CORD BLOOD & CORD BLOOD BANKING: AN OVERVIEW
2.1 Cord Blood, Cord Tissue, and Perinatal Stem Cell Banking
2.1.1  Public Cord Blood Banks
2.1.1.1  Economic Model of Public Cord Blood Banks
2.1.1.2  Cost Analysis for Public Banks
2.1.1.3  Relationship between Costs and Release Rates for Cord Blood Units (CBUs)
2.1.2  Private Cord Blood Banks
2.1.2.1  Cost Analysis for Private Cord Blood Banks
2.1.2.2  Economic Model of Private Cord Blood Banks
2.1.3  Hybrid Cord Blood Banks
2.2  Global Leaders within the Private Cord Blood and Tissue Banking Market
2.2.1  Comparing Cord Blood Banks
2.2.2  Leading Cord Blood Banks within the U.S.
2.2.3  Breakdown of Public, Private and Hybrid Banks within the U.S.
2.3  Percent Share of Parents Storing Cord Blood by Country/Region
2.4  Pricing for Processing and Storage at Leading Cord Blood and Tissue Banks
2.4.1  Rates Per Cord Blood Unit (CBU) within the U.S. and Europe
2.5  Annual Cord Blood Revenues for Leading Cord Blood Banks

3.1 American Association of Blood Banks (AABB)
3.2 Foundation for the Accreditation of Cellular Therapy (FACT)
3.3 FDA Registration
3.4 FDA Biologics License Application (BLA) License
3.5 Investigational New Drug (IND) for Cord Blood
3.6 Human Tissue Authority (HTA)
3.7 Therapeutic Goods Act (TGA) in Australia
3.8 International NetCord Foundation
3.9 AABB Accredited Cord Blood Facilities
3.10 FACT Accreditation for Cord Blood Banks

4.1 Hematopoietic Stem Cell Transplantations with Cord Blood Cells
4.2 Umbilical Cord Cells in Regenerative Medicine
5. CORD BLOOD PROCESSING TECHNOLOGIES
5.1 The Process of Separation
5.1.1  PrepaCyte-CB
5.1.2  Advantages of PrepaCyte-CB
5.1.3  Treatment Outcomes with PrepaCyte-CB
5.1.4  Hetastarch (HES)
5.1.5  AutoXpress (AXP)
5.1.6  SEPAX
5.1.7  Plasma Depletion Method (MaxCell Process)
5.1.8  Density Gradient Method
5.2  Comparative Merits of Different Processing Methods
5.2.1  Early-Stage HSC Recovery by Technologies
5.2.2  Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood
5.2.3  Late-Stage Recovery of HSCs from Cord Blood
5.3  HSC (CD45+) Recovery
5.4   Days to Neutrophil Engraftment by Technology
5.5  Anticoagulants used in Cord Blood Processing
5.5.1  Type of Anticoagulant and Cell Recovery Volume
5.5.2  Percent Cell Recovery by Sample Size
5.5.3  TNC Viability by Time Taken for Transport and Type of Anticoagulant
5.6  Cryopreservation of Cord Blood Cells
5.7  Bioprocessing of Umbilical Cord Tissue (UCT)
5.8  A Proposal to Improve the Utilization Rate of Banked Cord Blood

6.1 Cord Blood Cells for Research  6.2 Cord Blood Cells for Clinical Trials
6.2.1  Number of Clinical Trials involving Cord Blood Cells
6.2.2  Number of Clinical Trials using Cord Blood Cells by Geography
6.2.3  Number of Clinical Trials by Study Type
6.2.4  Number of Clinical Trials by Study Phase
6.2.5  Number of Clinical Trials by Funder Type
6.2.6  Clinical Trials Addressing Indications in Children
6.2.7  Select Three Clinical Trials Involving Children
6.2.7.1  Sensorineural Hearing Loss (NCT02038972)
6.2.7.2  Autism Spectrum (NCT02847182)
6.2.7.3  Cerebral Palsy (NCT01147653)
6.2.8  Clinical Trials for Neurological Diseases using Cord Blood and Cord Tissue
6.2.9  Umbilical Cord Blood (UCB) for Diabetes
6.2.10  Umbilical Cord Blood (UCB) in Cardiovascular Clinical Trials
6.2.11  Cord Blood Cells for Auto-Immune Diseases in Clinical Trials
6.2.12  Cord Tissue Cells for Orthopedic Disorders in Clinical Trials
6.2.13  Cord Blood Cells for Other Indications in Clinical Trials
6.3  Major Diseases Addressed by Cord Blood within Clinical Trials
6.4  Clinical Trials using Cord Tissue-Derived MSCs
6.5  Ongoing Clinical Trials using Cord Tissue
6.5.1  Cord Tissue-Based Clinical Trials by Geography
6.5.2  Cord Tissue-Based Clinical Trials by Phase
6.5.3  Cord Tissue-Based Clinical Trials by Sponsor Type
6.5.4  Companies Sponsoring Trials using Cord Tissue-Derived MSCs
6.6  Wharton’s Jelly-Derived MSCs in Clinical Trials
6.6.1  Wharton’s Jelly-Based Clinical Trials by Phase
6.6.2  Companies Sponsoring Wharton’s Jelly-Based Clinical Trials
6.7  Clinical Trials Involving Cord Blood Expansion Studies
6.7.1  Safe and Feasible Expansion Protocols
6.7.2  List of Clinical Trials involved in the Expansion of Cord Blood HSCs
6.7.3  Expansion Technologies
6.8  Scientific Publications on Cord Blood
6.9  Scientific Publications on Cord Tissue
6.10  Scientific Publications on Wharton’s Jelly-Derived MSCs
6.11  Published Scientific Papers on Cord Blood Cell Expansion
6.12  NIH Funding for Cord Blood Research

7.1 Factors Affecting Undecided Expectant Parents
7.2 Cord Blood Banks Known by Expectant Parents (Brand Recognition)
7.3 Factors Influencing Parental Choice of a Cord Blood Bank

8.1 Comparisons of Cord Blood versus Other Allograft Sources
8.1.1  Major Indications for HSCT within the U.S.
8.1.2  Trends in Allogeneic (Donor) HSCT within the U.S. by Recipient Age
8.1.3  Trends in Autologous (Patient-Derived) HSCT within the U.S. by Recipient Age
8.2  Breakdown of HSCT by Cell Source within Adult Patients
8.2.1  HSCTs by Cell Source within Pediatric Patients
8.3  Allogeneic HSCTs by Cell Source
8.3.1  Unrelated Donor Allogeneic HSCTs in Patients Under 18 Years
8.4  Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity
8.4.1  Likelihood of Finding an Unrelated Cord Blood Unit for Patients Under 20 Years
8.5  Probability of Using a Newborn’s Cord Blood
8.6  Cord Blood Utilization Trends
8.7  Number of Cord Blood Donors Worldwide
8.7.1  Number of CBUs Stored Worldwide
8.7.2  Number of CBUs, PBSCs and BMCs Shipped
8.7.3  Cord Blood Donors by Geography
8.7.3.1  Public Cord Blood Units Stored in Different Geographies
8.7.3.2  Number of Donors by HLA Typing
8.7.4  Searches Made by Transplant Patients for Donors/CBUs
8.7.5  Types of CBU Shipments (Single/Double/Multi)
8.7.6  TNC Count of CBUs Shipped for Children and Adult Patients
8.7.7  Shipment of Multiple CBUs
8.7.8  Percent Supply of CBUs for National and International Patients
8.7.9  Decreasing Rates of CBU Utilization
8.8  Top Ten Countries for Cord Blood Donation
8.8.1  HLA Typed Cord Blood Units (CBUs) by Continent
8.8.2  TNC Percentage of Banked Cord Blood Units (CBUs)
8.8.3  Total Number of CBUs, HLA-Typed Units by Country
8.9  Cord Blood Export/Import by E.U. Member States
8.9.1  Number of Donors and CBUs in Europe
8.9.2  Number of Exports/Imports of Cord Blood Units (CBUs) within E.U.
8.10  Global Exchange of Cord Blood Units

9.1  MSCs from Cord Blood and Cord Tissue
9.1.1  Potential Neurological Applications of Cord Blood-Derived Cells
9.1.2  Cord Tissue-Derived MSCs for Therapeutic Use
9.1.2.1  Indications Targeted by Umbilical Cord Tissue (UCT) MSCs in Clinical Trials
9.2  Current Consumption of Cord Blood Units by Clinical Trials
9.3  Leading Cord Blood Stem Cell Treatments within Clinical Trials
9.3.1  Acquired Hearing Loss (NCT02038972)
9.3.2  Autism (NCT02847182)
9.3.3  Cerebral Palsy (NCT03087110)
9.3.4  Hypoplastic Left Heart Syndrome (NCT01856049)
9.3.5  Type 1 Diabetes (NCT00989547)
9.3.6  Psoriasis (NCT03765957)
9.3.7  Parkinson’s Disease (NCT03550183)
9.3.8  Signs of Aging (NCT04174898)
9.3.9  Stroke (NCT02433509)
9.3.10  Traumatic Brain Injury (NCT01451528)

10.1 Cord Blood and Tissue Banking Market Size: Public vs. Private Banking
10.2 Cord Blood and Tissue Banking Market Size: By Indication

11.1  AllCells
11.1.1  Whole Blood
11.1.2  Leukopak
11.1.3  Mobilized Leukopak
11.1.4  Bone Marrow
11.1.5  Cord Blood
11.2  AlphaCord LLC
11.2.1  NextGen Collection System
11.3  Americord Registry, Inc.
11.3.1  Cord Blood 2.0
11.3.2  Cord Tissue
11.3.3  Placental Tissue 2.0
11.4  Be The Match
11.4.1  Hub of Transplant Network
11.4.2  Partners of Be The Match
11.4.3  Allogeneic Cell Sources in Be The Match Registry
11.4.4  Likelihood of a Matched Donor on Be The Match by Ethnic Background
11.5  Biocell Center Corporation
11.5.1  Chorionic villi after Delivery
11.5.2  Amniotic Fluid and Chorionic Villi during Pregnancy
11.6  BioEden Group, Inc.
11.6.1  Differences between Tooth Cells and Umbilical Cord Cells
11.7  Biovault Family
11.7.1  Personalized Cord Blood Processing
11.8  Cell Care
11.9  Cells4Life Group, LLP
11.9.1  Cells4Life’s pricing
11.9.2  TotiCyte Technology
11.9.3  Cord Blood Releases
11.10 Cell-Save
11.11 Center for International Blood and Marrow Transplant Research (CIBMTR)
11.11.1  Global Collaboration
11.11.2  Scientific Working Committees
11.11.3  Medicare Clinical Trials and Studies
11.11.4  Cellular Therapy
11.12  Cord Blood Center Group
11.12.1  Cord Blood Units Released
11.13  Cordlife Group, Ltd.
11.13.1  Cordlife’s Cord Blood Release Track Record
11.14  Core23 Biobank
11.15  Cord Blood Registry (CBR)
11.16  Cordlife Group, Ltd.
11.17  CordVida
11.18  Crioestaminal
11.18.1  Cord Blood Transplantation in Portugal
11.19  Cryo-Cell International, Inc.
11.19.1  Processing Method
11.19.2  Financial Results of the Company
11.19.3  Cryo-Cell International’s Pricing
11.20  CryoHoldco
11.21  Cryoviva Biotech Pvt. Ltd
11.22  European Society for Blood and Bone Marrow Transplantation (EBMT)
11.22.1  EBMT Transplant Activity
11.23  FamiCord Group
11.24  GeneCell International
11.25  Global Cord Blood Corporation (GCBC)
11.25.1  The Company’s Business
11.26  HealthBaby Hong Kong
11.26.1  BioArchive System Service Plan
11.26.2  MVE Liquid Nitrogen System
11.27  HEMAFUND
11.28  Insception Lifebank
11.29  LifebankUSA
11.29.1  Placental Banking
11.30 LifeCell International Pvt. Ltd.
11.31 MiracleCord, Inc.
11.32 Maze Cord Blood Laboratories
11.33 New England Cord Blood Bank, Inc.
11.34 New York Cord Blood Center (NYBC)
11.34.1  Products
11.34.2  Laboratory Services
11.35  PacifiCord
11.35.1  FDA-Approved Sterile Collection Bags
11.35.2  AXP Processing System
11.35.3   BioArchive System
11.36  ReeLabs Pvt. Ltd.
11.37  Smart Cells International, Ltd.
11.38  Stem Cell Cryobank
11.39  StemCyte, Inc.
11.39.1   StemCyte Sponsored Clinical Trials
11.39.1.1  Spinal Cord Injury Phase II
11.39.1.2  Other Trials
11.40  Transcell Biolife
11.40.1  ScellCare
11.40.2  ToothScell
11.41  ViaCord
11.42  Vita 34 AG
11.43  World Marrow Donor Association (WMDA)
11.43.1  Search & Match Service
11.44  Worldwide Network for Blood & Marrow Transplantation (WBMT)

FIGURE 2.1: Profit Margins of Select Private Cord Blood Banks
FIGURE 2.2: U.S. Cord Blood Banks by Size of Inventory
FIGURE 2.3: Proportion of Public, Private and Hybrid Banks in U.S.
FIGURE 2.4: Percent Share of Parents of Newborns Storing Cord Blood by Country/Region
FIGURE 2.5: Cord Blood Revenues for Companies
FIGURE 3.1: Percent Share of AABB Accredited Cord Blood Facilities by Country
FIGURE 5.1: Separation of Buffy Layer
FIGURE 5.2: PrepaCyte-CB
FIGURE 5.3: Hetastarch (HES)
FIGURE 5.4: AutoXpress II
FIGURE 5.5: SEPAX 2
FIGURE 5.6: Plasma Depletion (PD) Method (MaxCell Process)
FIGURE 5.7: Density Gradient Separation of Cord Blood
FIGURE 5.8: Early-Stage HSC Recovery from Cord Blood by Technologies
FIGURE 5.9: Mid-Stage HSC (CD34+/CD133+) Recovery from Cord Blood by Technologies
FIGURE 5.10: Late-Stage HSC Recovery from Cord Blood by Technologies
FIGURE 5.11: HSC (CD45+) Recovery Post Process from Whole Blood by Technologies
FIGURE 5.12: Days to Neutrophil Engraftment by Technology
FIGURE 5.13: Difference in TNC Recovery among Anticoagulants
FIGURE 5.14: Type of Anticoagulant and Cell Recovery Volume
FIGURE 5.15: Percent Cell Recovery by Sample Size
FIGURE 5.16: TNC Viability by Time Taken for Transport
FIGURE 5.17: Difference in Recovery of Viable TNC after Thawing
FIGURE 5.18: CD34+ Cell Count, CFU and Cell Apoptosis by Cryoprotectants
FIGURE 5.19: The Number of Stored and Transplanted CB Units in Korea-CORD by TNC
FIGURE 5.20: Number of Stored and Shipped CB Units and Utilization Rate by TNC Count
FIGURE 6.1: Number of Cord Blood Clinical Trials as Reported in PubMed.gov (2000 to Present)
FIGURE 6.2: Number of Cord Blood Clinical Trials by Geography
FIGURE 6.3: Number of Cord Blood Clinical Trials by Study Type
FIGURE 6.4: Number of Cord Blood Clinical Trials by Study Phase
FIGURE 6.5: Number of Cord Blood Clinical Trials by Funder Type
FIGURE 6.6: Percent Share of Indications in Children tested in Clinical Trials
FIGURE 6.7: Percent Share of Diseases in Ongoing Clinical Trials using Cord Blood Cells
FIGURE 6.8: Percent Share of Diseases in Clinical Trials using MSCs from Cord Tissue
FIGURE 6.9: Number of Cord Tissue-Based Clinical Trials by Geography as of June 2021
FIGURE 6.10: Cord Tissue-Based Clinical Trials by Study Phase
FIGURE 6.11: Cord Tissue-Based Clinical Trials by Funder Type
FIGURE 6.12: Wharton’s Jelly-Based Clinical Trials by Study Phase
FIGURE 6.13: Number of Published Scientific Papers on UCB, 2000 to Present
FIGURE 6.14: Number of Published Scientific Papers on Cord Tissue
FIGURE 6.15: Number of Published Scientific Papers on Wharton’s Jelly
FIGURE 6.16: Number of Published Scientific Papers on CB Expansion
FIGURE 7.1: Percent of Expectant Parents Who Have Heard About Cord Blood Banking
FIGURE 7.2: Undecided Expectant Parents about Cord Blood Banking
FIGURE 7.3: Brand Name Recognition of Cord Blood Banks by Expectant Parents
FIGURE 7.4: Factors Influencing the Choice of a Cord Blood Bank
FIGURE 8.1: Distribution of Cell Sources in HCTs as Reported in Be The Match
FIGURE 8.2: Comparisons of Cord Blood to other Allograft Sources
FIGURE 8.3: Major Indications for HTC in the U.S.
FIGURE 8.4: Trend in Allogeneic HCT in the U.S. by Recipient Age
FIGURE 8.5: Trends in Autologous HCT in the U.S. by Recipient Age
FIGURE 8.6: Transplants by Cell Source in Adult Patients, 2010 to Present
FIGURE 8.7: Transplants by Cell Source in Pediatric Patients <18 Years
FIGURE 8.8: Allogeneic HCTs by Cell Source Facilitated by NMDP/Be The Match
FIGURE 8.9: Unrelated Donor Allogeneic HCTs in Patients <18 Years/NMDP/Be The Match
FIGURE 8.10: Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity
FIGURE 8.11: Likelihood of Finding an Unrelated Cord Blood Unit for Patients <20 Years
FIGURE 8.12: Cumulative Probability of having a Stem Cell Transplant by Age
FIGURE 8.13: Cord Blood Utilization Trends  FIGURE 8.14: Number of UCB Donors Worldwide as Reported by WMDA
FIGURE 8.15: Number of CBUs Worldwide as Reported by WMDA, 2000 to Present
FIGURE 8.16: Unrelated BM, PBPC and CB Shipped per Year
FIGURE 8.17: Number of Umbilical Cord Blood Donors by Geography
FIGURE 8.18: Public Cord Blood Units Stored by Geography as Reported by the WMDA
FIGURE 8.19: Percent Shares of all Registered Donors by HLA Typing Level
FIGURE 8.20: Number of Searches Initiated by National Patients for Donors/CBU/Both
FIGURE 8.21: Types of CBU Shipments  FIGURE 8.22: TNC Count of CBUs Provided for Children and Adult Patients - Single
FIGURE 8.23: TNC Count of CBUs Provided for Children and Adult Patients - Multi
FIGURE 8.24: Percentage of HPC Products Provided for National and International Patients
FIGURE 8.25: Percentage of CB Units Provided for National and International Patients
FIGURE 8.26: Top Ten Countries with Number of Donors Listed per 10,000 Inhabitants
FIGURE 8.27: Percentage of HLA Typed CBUs Banked per Continent
FIGURE 8.28: Percentage TNC of Banked CBUs
FIGURE 8.29: Number of Donors per 10,000 Inhabitants by Select E.U. Countries
FIGURE 8.30: Global Exchange of Cord Blood Units
FIGURE 8.30: Global Shipments of CBUs by Geography
FIGURE 9.1:   Percent Shares of Indications Targeted by UCB-MSCs in Clinical Trials
FIGURE 9.2:   Percent Share of Clinical Indications using UCT-MSCs 162
FIGURE 9.3:   Number of UCB Units Released by Cord Blood Registry by Application
FIGURE 10.1: Global Cord Blood Banking Market Revenue by Geography through 2027
FIGURE 10.2: Percent Share of Global Cord Blood Banking Market Revenue by Geography
FIGURE 10.3: Percent Share of Global Cord Blood Banking Market, Public vs. Private
FIGURE 10.4: Percent Share of Cord Blood Banking Market by Indication
FIGURE 11.1: Growth of CBUs on the Be The Match Registry
FIGURE 11.2: Diversity of CBUs on Be The Match Registry
FIGURE 11.3: Number of CBUs on Be The Match Registry by Race and Ethnicity
FIGURE 11.4: Diversity of CBUs in Be The Match Registry
FIGURE 11.5: Cell Sources for Allogeneic HCT Facilitated by Be The Match Registry
FIGURE 11.6: Likelihood of a Matched Donor on Be The Match Registry by Ethnicity
FIGURE 11.7: Percent Recovery of Viable Cells by TotiCyte Technology
FIGURE 11.8: Growth in Number of New Transplant Patients Registered with the CIBMTR
FIGURE 11.9: New Patients per Year Registered with CIBMTR
FIGURE 11.10: Transplant Patients by Graft Source Registered with CIBMTR
FIGURE 11.11: Number of Cord Blood Units Stored in CBR and its Competitors
FIGURE 11.12: Key Figures of Sales Revenues and Gross Profits for Cordlife
FIGURE 11.13: Cryo-Cell International’s Revenues, 2016 to Present
FIGURE 11.14: Revenue and Gross Profit for GCBC
FIGURE 11.15: Percent Share of Units Released by Indication
FIGURE 11.16: Key Figures of Sales Revenues & Gross Profits for Vita 34
FIGURE 11.17: Search Types in WMDA Search & Match Service, 2017 to Present

TABLE 2.1:  An Overview of Public Cord Blood Banks
TABLE 2.2:  International Prices of Cord Blood Unit
TABLE 2.3:  Prices of Cord Blood Units in NMDP Banks in the U.S.
TABLE 2.4:  An Overview of Private Cord Blood Banks
TABLE 2.5:  Profit Margins of Select Private Cord Blood Banks
TABLE 2.6:  An Overview of Hybrid Cord Blood Banks
TABLE 2.7:  World’s 12 Largest Private Cord Blood Bank Operators
TABLE 2.8:  Comparison of Three Largest Private Banks in U.S.
TABLE 2.9:  List of Public, Private and Hybrid Cord Blood Banks in the U.S.
TABLE 2.10: Pricing for Storage in Commercial Banks
TABLE 2.11: Rate per Cord Blood Unit in the U.S. & Europe
TABLE 2.12: Cord Blood Revenues for Major Four Companies
TABLE 3.1:  AABB Accredited Cord Blood Facilities
TABLE 3.2:  Select FACT Accredited Cord Blood Facilities
TABLE 4.1:  Indications for the Use of UCB-Derived Stem Cells for Transplantation
TABLE 4.2:  Indications for the Use of UCB-Derived Stem Cells for Regenerative Medicine
TABLE 5.1:  Advantages of PrepaCyte-CB
TABLE 5.2:  Treatment Outcomes with PrepaCyte-CB
TABLE 6.1:  U.S. Cord Blood Banks Supplying Cord Blood for Research
TABLE 6.2:  Number of Cord Blood Clinical Trials by Geography
TABLE 6.3:  Number of Cord Blood Clinical Trials by Study Type
TABLE 6.4:  Number of Cord Blood Clinical Trials by Study Phase
TABLE 6.5:  Number of Cord Blood Clinical Trials by Funder Type
TABLE 6.6:  Percentage Share of Indications in Children Tested within Clinical Trials
TABLE 6.7:  Cord Blood Clinical Trials involving Children
TABLE 6.8:  Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Neurological Diseases
TABLE 6.9:  Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Diabetes
TABLE 6.10: Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Cardiovascular Trials
TABLE 6.11: Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Auto-Immune Diseases
TABLE 6.12: Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Orthopedic Disorders
TABLE 6.13: Ongoing Clinical Trials using Umbilical Cord Blood (UCB) for Other Indications
TABLE 6.14: Clinical Trials using MSCs from Cord Tissue
TABLE 6.15: Number of Cord Tissue-Based Clinical Trials by Geography
TABLE 6.16: Number of Cord Tissue-Based Clinical Trials by Study Phase
TABLE 6.17: Number of Cord Tissue-Based Clinical Trials by Funder Type
TABLE 6.18: Select Cord Tissue-Based Clinical Trials by Commercial Entities, 2021
TABLE 6.19: Wharton’s Jelly-Based Clinical Trials by Phase
TABLE 6.20: Wharton’s Jelly-Based Clinical Trials by Commercial Entities
TABLE 6.21: Clinical Trials in Cord Blood-Derived Cell Expansion by Country
TABLE 6.22: Clinical Trials of Cell Expansion Studies by Stages in Development
TABLE 6.23: Twenty Clinical Trials involved in the Expansion of Cord Blood HSCs
TABLE 6.24: Cord Blood Expansion Approaches
TABLE 6.25: Select NIH Funding for Umbilical Cord Blood Research
TABLE 8.1:  Comparisons of Cord Blood to other Allograft Sources in Transplantation
TABLE 8.2:  Number of HCTs Performed in the U.S. as reported to CIBMTR by Disease
TABLE 8.3:  No. of Cord Blood Units Available Worldwide According to WMDA
TABLE 8.4:  Unrelated BM, PBPC and CB Shipped, 1997-2020
TABLE 8.5:  Total Number of Cord Blood Donors and Cord Blood Units by Country
TABLE 8.6:  Number of Donors and CBUs by E.U. Country
TABLE 8.7:  Number of Exports/Imports of Cord Blood Units (CBUs) in E.U.
TABLE 9.1:  Clinical Trials using Cord Blood-Derived MSCs as Interventions
TABLE 9.2:  Clinical Trials using Umbilical Cord Tissue (UCT) MSCs as Interventions
TABLE 10.1: Global Cord Blood Banking Market Revenue by Geography through 2027
TABLE 11.1: AlphaCord’s Pricing  TABLE 11.2: Growth of Cord Blood Units in the Be The Match Registry
TABLE 11.3: Diversity of CBUs on Be The Match Registry
TABLE 11.4: Number of CBUs on Be The Match Registry by Race and Ethnicity
TABLE 11.5: Cell Care’s pricing for Processing and Storage
TABLE 11.6: Cells4Life’s pricing for Cord Blood, Cord Tissue, Amnion and Placental Cells
TABLE 11.7: Cord Blood and Cord Tissue Products Released from Cells4Life
TABLE 11.8: Distribution of Transplant Patients by Graft Source Registered with CIBMTR
TABLE 11.9: Distribution of Transplant Patients by Indication Registered with CIBMTR
TABLE 11.10: Cord Blood Units Released from the Cord Blood Center Group
TABLE 11.11: Cordlife’s Cord Blood Release Track Record
TABLE 11.12: Core23 Biobank’s Processing and Storage Fees
TABLE 11.13: Cryo-Cell International’s Revenues by Year
TABLE 11.14: Cryo-Cell International’s Pricing for Processing and Storage
TABLE 11.15: Allogeneic and Autologous Infusions by Indication Reported in EBMT
TABLE 11.16: GeneCell Internationals Prepaid Storage Plans
TABLE 11.17: Selected Financial Data for Global Cord Blood Corporation (GCBC)
TABLE 11.18: Insception Lifebank’s Pricing
TABLE 11.19: LifeCell International’s Pricing
TABLE 11.20: Cost Comparison of MiracleCord versus Competitors
TABLE 11.21: Maze Cord Blood Laboratory’s Payment Plans
TABLE 11.22: Comparison of Pricing of NECBB with Competitors
TABLE 11.23: Stem Cell Cryobank’s Pricing for Processing and Storage